CARTProduct Variations
| Product # | Price | Quantity | |
|---|---|---|---|
| VD-OEIA-1033-0005-5mg | $120 | ||
| VD-OEIA-1033-0025-25mg | $420 |
AZD0530 difumarate
$120.00 – $420.00
Product Specification
-
Appearance:
N/A
-
CAS Number:
379231-04-6
-
Cat.number:
VD-OEIA-1033
-
Formula:
C27H32ClN5O5.2C4H4O4
-
MW:
774.18
-
Purity:
>99%
-
Solubility:
DMSO and water.
-
Storage:
N/A
-
Synonyms:
Saracatinib
-
Size:
25mg, 5mg
Description
An orally bioavailable tyrosine kinase inhibitor, specifically targeting Src and Abl, those kinases often overexpressed in chronic myeloid leukema cells. Optimal water-soluble form.
1. H Laurent et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 2006, 49(22), 6465-6488.
2. YM Chang et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 1–11.
3. PM Gwanmesia et al. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. BMC Cancer 2009, 9, 53.
4. TP Green et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology 2009, 3(3), 248-261. 5. C Dulsat et al. Saracatinib. Drugs Fut. 2009, 34(2), 106.
Reviews
There are no reviews yet.